Methods of treating neurodegenerative disorders comprising DNA methyltransferase inhibitors
The present disclosure provides a method of treating a neurodegenerative disorder, the method comprising administering a DNA methyltransferase inhibitor.
1. A method to reduce symptoms associated with Huntington's disease in a subject in need thereof, the method comprising administering to the subject a DNA methylation inhibitor, wherein the DNA methylation inhibitor is a nucleoside analog DNA methyltransferase (DNMT) inhibitor, and wherein the DNMT inhibitor decreases the levels of mutant Htt aggregates.
2. The method of claim 1 , wherein the DNMT inhibitor is decitabine or FdCyd.
3. The method of claim 1 , wherein the DNA methylation inhibitor is administered by the intracerebroventricular (icy) route.
4. The method of claim 1 , wherein the DNA methylation inhibitor is administered intravenously, intramuscularly, or subcutaneously.
5. A method to reduce mutant huntingtin protein (Htt)-induced neurotoxicity, the method comprising contacting a nucleoside analog DNA methyltransferase (DNMT) inhibitor to neurons.
6. The method of claim 5 , wherein the DNMT inhibitor is decitabine or FdCyd.
7. The method of claim 5 , wherein the neurons are in vivo.
8. A method of preventing the development of the symptoms associated with Huntington's disease in a subject at risk of developing Huntington's disease, the method comprising administering to the subject a DNA methylation inhibitor; wherein the DNA methylation inhibitor is a nucleoside analog DNA methyltransferase (DNMT) inhibitor, and the DNMT inhibitor decreases the levels of mutant Htt aggregates.
9. The method of claim 8 , wherein the DNMT inhibitor is decitabine or FdCyd.
10. The method of claim 8 , wherein the DNA methylation inhibitor is administered by the intracerebroventricular (icy) route.
11. The method of claim 8 , wherein the DNA methylation inhibitor is administered intravenously, intramuscularly, or subcutaneously.